SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2025
Commission file number: 001-35223
_______________________
BioLineRx Ltd.
(Translation of registrant’s name into English)
_______________________
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
_______________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
BioLineRx Ltd. (the “Registrant”) announces
that it will hold an Annual Meeting of Shareholders on June 29, 2025, at 3:00 p.m. (Israel time), at the Registrant’s office, Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel. The Notice of Annual General Meeting and Proxy
Statement, the related proxy card and voting instruction form for holders of American Depositary Shares are attached to this Report on Form 6-K as Exhibit 99.1, Exhibit
99.2 and Exhibit 99.3, respectively, and incorporated herein by reference.
This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by
the registrant under the Securities Act of 1933.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
BioLineRx Ltd.
|
|
|
By:
|
/s/ Philip A. Serlin
|
|
|
|
Philip A. Serlin
|
|
|
|
Chief Executive Officer
|
|
Dated: May 23, 2025